Corporate Member Update- Merck: KEYTRUDA® Additional Indication

Corporate Member Update- Merck: KEYTRUDA® Additional Indication

KEYTRUDA®
July, 2020

Merck is pleased to announce that KEYTRUDA® (pembrolizumab) injection 100 mg has been approved by the FDA for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. The FDA has also approved KEYTRUDA® (pembrolizumab) for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Please read the updates below for additional information!

KEYTRUDA(R) (pembrolizumab): Additional Indication

KEYTRUDA(R) (pembrolizumab): Additional Indication2

KEYTRUDA(R) (pembrolizumab): Additional Indication3

The Medically Unlikely Edit Value for KEYTRUDA(R) (pembrolizumab) Has Been Modified as of July 1, 2020
 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members